GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Poviztra vs Wegovy in India — Same Molecule, Different Distribution Strategy

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Poviztra and Wegovy are pharmacologically identical — both contain Novo Nordisk's semaglutide for obesity. Wegovy is Novo Nordisk's direct India brand; Poviztra is distributed by Emcure under a Novo Nordisk partnership, targeted at tier-2 and tier-3 city access. After Emcure's April 2026 price cut, Poviztra runs ₹3,999–8,999/month vs Wegovy's ₹5,660–16,400/month. Same outcomes; different price points and distribution depth.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Poviztra vs Wegovy — at a glance

AttributePoviztraWegovy
Active ingredientSemaglutide 2.4 mgSemaglutide 2.4 mg
InnovatorNovo NordiskNovo Nordisk
India distributorEmcure Pharma (exclusive)Novo Nordisk India direct
Indication (India)Obesity / Chronic Weight ManagementObesity / Chronic Weight Management
Launch dateDecember 20252025–2026
Dose strengths0.25, 0.5, 1.0, 1.7, 2.4 mg weekly0.25, 0.5, 1.0, 1.7, 2.4 mg weekly
Pen formatPre-filled disposable penPre-filled pen
Approx. monthly price (India, 2026)₹3,999–8,999 (post April cut)₹5,660–16,400
Distribution depthTier-2 / Tier-3 cities + metrosPrimarily tier-1 metros + online pharmacies
Sales force1,000+ Emcure field repsNovo Nordisk India's established team
Prescription requiredYes (Schedule H)Yes (Schedule H)

Efficacy — what the trials show

Poviztra

Poviztra carries identical efficacy to Wegovy — the molecule is the same. STEP-1 trial outcomes (NEJM 2021): mean 14.9% body weight loss at 2.4 mg over 68 weeks. STEP-2 in T2D-comorbid patients: 9.6%. SELECT trial cardiovascular protection (20% MACE reduction) applies because it's the same molecule. Emcure has not run separate Indian Phase III trials for Poviztra; the regulatory pathway relies on Novo Nordisk's existing clinical data.

Wegovy

Wegovy's STEP-1 pivotal trial: 14.9% mean weight loss at 2.4 mg over 68 weeks vs 2.4% placebo. STEP-UP (Wegovy HD at 7.2 mg) pushing closer to tirzepatide-tier efficacy. SELECT trial: 20% MACE reduction in patients with obesity + established cardiovascular disease (without diabetes). Same outcomes as Poviztra — these are molecule-level outcomes, not brand-specific.

Cost in India (2026)

Poviztra

Poviztra: ₹3,999–8,999/month after Emcure's April 2026 price cut (average 47% reduction across dose strengths from the original ₹8,790 starter dose). The aggressive pricing reflects Emcure's strategy to compete with Indian generic semaglutides on price while retaining the Novo Nordisk innovator-quality positioning.

Wegovy

Wegovy: ₹5,660–16,400/month depending on dose. The 2.4 mg maintenance dose runs at the higher end. Novo Nordisk has held Wegovy's direct pricing relatively stable through 2026 while Poviztra absorbs the price-competition pressure in the Indian market.

Side effects

Poviztra

Identical to Wegovy — same molecule. Nausea (~44%), diarrhea (~32%), vomiting (~25%) peak during 1.7 → 2.4 mg titration. Indian patients on traditional rich diets during titration report higher GI intolerance; nutritionist co-management during the first 8-12 weeks helps. Rare but important: pancreatitis, gallbladder events, retinopathy in poorly-controlled diabetics.

Wegovy

Identical side-effect profile to Poviztra. STEP-1 data: nausea 44%, diarrhea 32%, vomiting 25%. Long-term real-world safety data is the most extensive among GLP-1 weight-loss agents. Discontinuation due to adverse events: ~6-7% in trials.

Which one should you consider?

Pick Poviztra if

  • ✓You want the Novo Nordisk innovator-quality molecule at significantly lower cost
  • ✓You're in a tier-2 or tier-3 Indian city where Wegovy stock may be patchy
  • ✓You're cost-sensitive but prefer the innovator manufacturer over generic
  • ✓Emcure's patient-support programme is available in your area

Pick Wegovy if

  • ✓You're in a tier-1 metro with reliable Wegovy stock and your doctor prefers it
  • ✓Your endocrinologist has the most prescribing experience with Wegovy specifically
  • ✓You're documenting therapy for international insurance or travel purposes (Wegovy brand widely recognized)
  • ✓You access the drug through a hospital pharmacy that stocks Wegovy directly

Frequently asked questions

Is Poviztra the same as Wegovy?+
The active molecule is identical — both are Novo Nordisk's semaglutide 2.4 mg for obesity. The difference is distribution: Wegovy is Novo Nordisk's direct India brand, Poviztra is the Emcure-distributed brand under a Novo Nordisk partnership. Same outcomes, different commercial routes and prices.
Why did Emcure launch Poviztra if Wegovy already exists?+
Distribution depth. Novo Nordisk's direct India sales force concentrates on tier-1 metros and major hospital networks. Emcure has a 1,000+ field force that reaches tier-2 and tier-3 cities. The partnership lets Novo Nordisk extend reach without building parallel infrastructure, while Emcure captures revenue in a category where it lacked an offering.
Is Poviztra a generic or an innovator brand?+
It's the innovator molecule (Novo Nordisk's semaglutide) distributed under a different brand name. Technically not a "generic" in the bioequivalence sense — Poviztra is the original Novo Nordisk product, just commercialized through Emcure rather than Novo Nordisk's own field force.
How much cheaper is Poviztra than Wegovy?+
After Emcure's April 2026 price cut: roughly 30-45% cheaper at equivalent doses. Poviztra: ₹3,999–8,999/month vs Wegovy ₹5,660–16,400/month. The gap is widest at maintenance doses (1.7-2.4 mg) where Wegovy pricing is highest.
Should I switch from Wegovy to Poviztra to save money?+
Discuss with your endocrinologist first. The molecule is identical, so clinical outcomes shouldn't differ. Practical considerations: confirm your local pharmacy stocks Poviztra, verify your titration dose is available, and ensure you're not on a hospital protocol that mandates Wegovy specifically. Most patients can switch without clinical issues.
Where can I buy Poviztra in India?+
Through Emcure's distribution network — major retail pharmacy chains (Apollo Pharmacy, MedPlus, Wellness Forever), online prescription pharmacies (1mg, PharmEasy, Apollo 24/7), and hospital pharmacies in tier-1, tier-2, and tier-3 cities. Emcure's field force has been specifically deployed to support tier-2/3 access, so smaller-city availability is typically better than Wegovy.
Are Indian generic semaglutides (like Sundae, Noveltreat) cheaper than Poviztra?+
Yes — Indian generics from Sun Pharma (Noveltreat, ₹750–2,000), Cipla, Zydus, Eris (Sundae, ₹220/shot) are still cheaper than Poviztra at most dose strengths. The trade-off: generics are bioequivalent but use different pen designs and manufacturer support. For pure cost minimisation, Indian generics win; for innovator-molecule preference, Poviztra is the middle path between Wegovy and the cheapest generics.

Related comparisons

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Noveltreat vs Sematrinity

Noveltreat vs Sematrinity in India — Same Molecule, Different Indication

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.